Access Biotechnology
New York, New York, United StatesFounded 2016
Access Biotechnology is the life science investment arm of Access Industries, focusing on private and public biopharma companies developing transformative therapies for conditions with high unmet needs. It invests across a broad range of stages, from discovery-stage technology platforms to late-stage clinical programs.
56% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (51% of deals). Average disclosed round size is $125.3M (across 36 rounds with reported amounts).
Portfolio
29
Fund Size
—
Top Stage
Series B
Last 12 Mo
3
Team
DB
Dan Becker
Managing Director
LR
Liam Ratcliffe
Managing Director
AS
Aliyah Silver
Associate
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
39 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Draig Therapeutics | Series B | $65M | Jul 2026 |
 Recludix Pharma | Series B | — | Jan 2026 |
 OnKure Therapeutics | Series C | $150M | Jan 2026 |
| HHemab | Series C | $157M | Oct 2025 |
| Draig Therapeutics | Series A | $140M | Jun 2025 |
 Surrozen | Series D | $175M | Mar 2025 |
 Latigo Biotherapeutics | Series B | $150M | Mar 2025 |
| Draig Therapeutics | Series A | $140M | Jan 2025 |
 Halda | Series B | $126M | Aug 2024 |
| HHalda Therapeutics | Series B | $126M | Jan 2024 |
 Mariana Oncology | Series B | $175M | Sep 2023 |
| UUpstream Bio, Inc. | Series B | $200M | Jun 2023 |
| HHemab Therapeutics Holdings | Series B | $135M | Feb 2023 |
| HHemab | Series B | $135M | Feb 2023 |
| AAcelyrin, Inc | Series C | $300M | Sep 2022 |
| UUpstream Bio, Inc. | Series A | $200M | Jun 2022 |
 Nimbus | Unknown | $125M | Jan 2022 |
 Curie Therapeutics Inc. | Series A | $75M | Dec 2021 |
| Mariana Oncology | Series A | $75M | Dec 2021 |
 Disc Medicine | Series B | $90M | Sep 2021 |
 Climb Bio | Series B | $60M | May 2021 |
| EEliem Therapeutics | Series B | $60M | May 2021 |
 DTx Pharma | Series B | $100M | Mar 2021 |
 Pandion Therapeutics | Series B | — | Apr 2020 |
| VVerona Pharma PLC | Unknown | $200M | Jan 2020 |
Page 1 of 2
Top Co-Investors
RA Capital Management18 shared
Deep Track Capital12 shared
Atlas Venture8 shared
OrbiMed8 shared
Sanofi Ventures6 shared
Rock Springs Capital6 shared
Samsara BioCapital6 shared
Canaan Partners6 shared
Alexandria Venture Investments5 shared
SR One5 shared
Westlake Village BioPartners4 shared
Novo Holdings A/S4 shared
Vivo Capital4 shared
Surveyor Capital4 shared
SV Health Investors4 shared
Marshall Wace4 shared
Bain Capital Life Sciences4 shared
Boxer Capital4 shared
Maj Invest4 shared
HealthCap4 shared
Last updated: 20 October 2026